Introduction to a Closed Tibial Fracture Animal Model

The closed tibial fracture animal model serves as a gold-standard in vivo platform in medical research, mimicking the pathological process of human fractures characterized by “intact skin and no communication with the external environment.” Rat or mouse models are commonly employed, utilizing a custom‑designed three‑point bending fracture apparatus (Einhorn device) to induce precise transverse tibial fractures under blunt impact, accompanied by a degree of soft‑tissue contusion. The model’s principal advantage lies in maintaining a sterile microenvironment at the fracture site and preserving the integrity of the surrounding soft tissues, thereby faithfully reproducing the sequential natural healing cascade observed clinically after closed fractures—namely, localized hematoma formation, acute inflammatory chemotaxis, cartilaginous callus transition, and eventual hard callus remodeling. Consequently, this model is ideally suited for evaluating systemic pharmacological interventions (e.g., hormones, metabolic agents), the biomechanics of minimally invasive internal fixation, and early bone‑repair signaling pathways.

Service Advantages of the Aniphe BioLab Tibial Fracture Animal Model Platform

Aniphe BioLab's tibial fracture animal model platform is dedicated to research in bone repair and bone regeneration, having established a stable and well‑validated system for constructing and evaluating tibial fracture models. It offers clients end‑to‑end services, from model establishment to endpoint assessments.

	The model is stable and reliable. Standardized fracture preparation and internal fixation procedures ensure accurate fracture positioning and excellent inter-batch consistency.
	Multidimensional Evaluation System It encompasses X-ray, micro-CT, histopathology, bone histomorphometry, and biomechanical testing.
	Enhanced testing platform HE staining, Masson’s trichrome staining, IHC, and molecular biology assays can be performed.
	End-to-end QA management Strictly adhere to SOPs and the quality management system to ensure that the modeling process is standardized and that experimental data are authentic and traceable.
	Customized Research Services The fracture type, fixation method, observation period, and endpoint evaluation criteria can be tailored to meet the specific requirements of each project, thereby accommodating diverse research objectives.

Modeling cycle	4–12 weeks
Laboratory animals	SD or Wistar rats
Positive drug	Bone morphogenetic protein‑2 (BMP‑2), parathyroid hormone (PTH 1‑34, such as teriparatide), bisphosphonates (e.g., sodium alendronate—though in fracture‑healing studies they are typically used in delayed‑healing models for comparison), and anti‑sclerostin antibodies (e.g., romosozumab), among others.
Application areas	Research on the cellular and molecular mechanisms of fracture healing (including endochondral ossification), the healing characteristics of osteoporotic fractures, phenotypic analysis in gene‑knockout and transgenic mice, and pharmacological evaluation of novel drugs with bone‑anabolic or anti‑resorptive effects.

Construction of an Animal Model of Tibial Fracture

The three-point bending fracture model of the mid‑shaft tibia is a widely used, standardized fracture model in studies of fracture healing. In this model, the tibial shaft of experimental animals—such as mice or rats—is typically stabilized with an intramedullary nail or Kirschner wire, after which a three‑point bending apparatus applies an instantaneous mechanical load to the mid‑shaft, inducing a transverse or short oblique fracture. This approach effectively mimics clinical closed long‑bone fractures and offers advantages such as minimal invasiveness, precise fracture location, and excellent reproducibility. Following model establishment, the entire fracture‑healing process—including inflammatory responses, cartilaginous callus formation, callus mineralization, and bone remodeling—can be observed, making this model extensively employed in investigations of bone‑repair mechanisms and in the evaluation of therapeutic strategies involving drugs, stem cells, exosomes, and bone‑regenerative materials.